Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The hepatitis C virus
3. The HCV genome
4. The HCV replication cycle
5. Current standard therapy
6. Interferon development
7. Therapeutic failure of current standard therapy
8. Ribavirin
9. Ribavirin mechanism of action
10. Antiviral and GTP depletion correlation
11. Differential response to standard therapy
12. Selective inhibitors of HCV replication
13. The NS2 cysteine protease
14. The HCV NS3 serine protease
15. NS3 protease product based inhibitors
16. Proof of concept with BILN-2061 (Ciluprevir)
17. Telaprevir monotherapy
18. Telaprevir + PEG-IFN + RBV
19. Other protease inhibitors of HCV in development
20. Protease inhibitors resistance mutations
21. Protease inhibitor - TMC435350
22. The NS3 helicase as an antiviral target
23. NS4A/NS3 inhibitors
24. NS4B as an antiviral target
25. NS5A as an antiviral target
26. NS5A inhibitor (BMS-790052)
27. The NS5B RNA dependent RNA polymerase
28. Nucleoside inhibitors
29. Non-nucleoside HCV inhibitors (1)
30. Non-nucleoside HCV inhibitors (2)
31. Non-nucleoside HCV inhibitors (3)
32. Non-nucleoside HCV inhibitors (4)
33. Non-nucleoside NS5B combination therapy
34. Imidazopyridines (Tegobuvir)
35. Tegobuvir + Telaprevir
36. Triple combinations
37. Cyclophilin binding HCV inhibitor
38. Alisporivir efficiently clears HCV replicon
39. Alisporivir combination with Telaprevir
40. Selecting Alisporivir resistant replicons
41. Alisporivir resistance with other HCV inhibitors
42. D320E contributes most to the resistance
43. Prevalence of D320E in euHCV database
44. Role of NS5A or NS5B in resistance
45. Swapping of NS5A results in resistance transfer
46. Wild type and CypA knock down studies
47. Impact of mutations in Alisporivir resistant NS5A
48. Cis-trans isomerase activity of cyclophilins
49. D320E peptide mutation effect on cis-trans
50. Working hypothesis
51. Conclusion

Topics Covered

• The HCV genome and replication cycle
• Interferon development
• Ribavirin
• Antiviral and GTP depletion correlation
• Selective inhibitors of HCV replication
• The NS2 cysteine and the NS3 serine proteases
• Protease inhibitors
• The NS3 helicase as an antiviral target
• NS4A/NS3, NS4B and NS5A as antiviral targets
• The NS5B RNA dependent RNA polymerase
• Nucleoside and non-nucleoside HCV inhibitors
• Double and triple combination therapies
• Debio-025
• Resistance to HCV inhibitors
• D320E peptide mutation effect
• Role of NS5A or NS5B in resistance
• Wild type and CypA knock down studies
• Cis-trans isomerase activity of cyclophilins

Links

Series:

• Antivirals

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Neyts, J. (2011, August 31). Towards the development of potent therapy against the hepatitis C virus [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/XPHQ1534.
Export Citation (RIS)

Publication History

• Published on August 31, 2011
• Archived on February 25, 2021

Financial Disclosures

• Prof. Johan Neyts has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.